UNASSIGNED: To investigate the efficacy of intravitreal ranibizumab (IVR) combined with laser photocoagulation for @entity146 posterior @entity989 (AP- @entity6109 ) @entity1 with @entity548 , we conducted a retrospective observational case series study. A total of 37 eyes of 20 @entity1 ' medical records were reviewed. @entity1 first received IVR (0.25   mg/0.025   mL) and later photocoagulation. The mean postconceptual age of injection was 34.6    1.4 weeks, and the mean follow-up period was 39.3    8.3 weeks. During the follow-up, 96.6% eyes had various degree of rapid absorption of @entity548 after IVR. The mean time of received first photocoagulation after IVR was 4.8    2.9 weeks. Ten (27.0%) eyes received second laser therapy and the mean time of second laser therapy after IVR was 3.2    0.8 weeks. All eyes exhibited adequate regression of @entity6109 and were stable with attached retina. Fibrosis membrane was observed in seven eyes (18.9%) and three of them demonstrated mild ectopic macula. No significant side effects related to IVR were observed. So IVR could be conducted as primary treatment of AP- @entity6109 associated with @entity548 , which can improve the fundus visibility, followed by conventional photocoagulation. Further randomized controlled trials are necessary to compare the clinical efficacy and safety with conventional interventions.

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of @entity146 with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity548 :: ('MESH:D006470', 'Disease') :: ['vitreous hemorrhage'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy of prematurity'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity6109 :: ('MESH:C536382', 'Disease') :: ['ROP']
@entity548 :: (MESH:D006470,Disease) :: ['Vitreous Hemorrhage']
